Organization
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
16 abstracts
Abstract
NCI MATCH (EAY131) arm Z1D: Retrospective evaluation of attributions of adverse events experienced on nivolumab in patients with MSI-high tumors.Org: University of Maryland, Germantown, MD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, Cancer Diagnosis Program, National Cancer Institute, Rockville, MD, Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD,
Abstract
An open-label phase 1 study to investigate SGNCEACAM5C/SAR445953 in adults with advanced solid tumors (SGNCEA5C-001).Org: START San Antonio, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Mayo Clinic Cancer Center, Beth Israel Deaconess Medical Center, START Mountain Region,
Abstract
Trainee-led quality improvement (QI) project examining PCP prophylaxis in patients on chronic, high-dose corticosteroids.Org: Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Johns Hopkins University Bloomberg School of Public Health,
Abstract
Contemporary management of patients with advanced melanoma: Utility of an online interactive decision support tool to assess concordance of healthcare professional treatment patterns with expert recommendations.Org: Clinical Care Options, LLC, Stanford Cancer Institute, University of California, San Francisco, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD,
Abstract
Blood-based markers of differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial.Org: Johns Hopkins University School of Medicine, University of Minnesota Masonic Cancer Center, Minneapolis, MN, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,
Abstract
Response to neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in oncogene-driven resectable non-small cell lung cancer (NSCLC).Org: Johns Hopkins University Bloomberg School of Public Health, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Memorial Sloan Kettering Cancer Center, RI-MUHC,
Abstract
Preliminary antitumor activity of the combination of COM701 + BMS-986207 + nivolumab in patients with recurrent, metastatic MSS endometrial cancer.Org: West Cancer Center & Research Institute, University of Chicago, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Massachusetts General Hospital,
Abstract
Prevalence of germline variants in patients with pancreatic neuroendocrine tumors.Org: Johns Hopkins University School of Medicine, University of Texas MD Anderson Cancer Center, University of Pennsylvania, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, University of Texas at MD Anderson Cancer Center,
Abstract
ASCENT-05/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple-negative breast cancer (TNBC) and residual disease after neoadjuvant therapy (NAT) and surgery.Org: Dana-Farber Cancer Institute, University of Pennsylvania, The Cancer Institute Hospital of JFCR, Tokyo, Japan, University of California Comprehensive Cancer Center, University of North Carolina at Chapel Hill,
Abstract
A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.Org: University of Okahoma Health Sciences Center, Carolina BioOncology Institute, Sarah Cannon Research Institute/Tennessee Oncology, University of Michigan, START Midwest, Grand Rapids, MI,
Abstract
Phase 1 study of WNT pathway Porcupine inhibitor CGX1321 and phase 1b study of CGX1321 + pembrolizumab (pembro) in patients (pts) with advanced gastrointestinal (GI) tumors.Org: Dana-Farber Cancer Institute, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Georgetown University Hospital, Washington, DC, Lombardi Comprehensive Cancer Center, START San Antonio,
Abstract
A phase 1 study of the SYK inhibitor fostamatinib and weekly paclitaxel for recurrent platinum-resistant ovarian cancer.Org: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, University of Pennsylvania Health System, Johns Hopkins Kimmel Cancer Center, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center,
Abstract
Circulating tumor cells in patients with hormone receptor-positive, HER2-negative metastatic breast cancer receiving palbociclib with fulvestrant after progression on palbociclib with an aromatase inhibitor.Org: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University Bloomberg School of Public Health, RPS Hematology Oncology, Allegheny General Hospital, University of Michigan,
Abstract
Real world impact of hepatocellular carcinoma stage and hepatic function on health-related quality of life.Org: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Baltimore, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine,
Abstract
Randomized placebo-controlled trial of intravenous vitamin C plus docetaxel in metastatic prostate cancer.Org: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Karmanos Cancer Institute, Wayne State University School of Medicine,
Abstract
Survival outcomes of liposomal irinotecan in patients with advanced pancreatic adenocarcinoma previously treated with conventional irinotecan-based chemotherapy: A single-institution experience.Org: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Baltimore, MD,